Advance Purchase Agreement

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-02ee22-2021-10-20T16:33:23+01:00",
    "date": "2021-10-20T16:33:23+01:00",
    "ocid": "ocds-h6vhtk-02ee22",
    "description": "Additional information: contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market. Also, given significant competition to bring to the market a successful vaccine, provision of the contract term is valuable information to competitors that may impact negotiations/future competition.",
    "initiationType": "tender",
    "tender": {
        "id": "2611/09/2020",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Advance Purchase Agreement",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "33651600",
            "description": "Vaccines"
        },
        "mainProcurementCategory": "goods",
        "description": "Procurement of the Covid-19 Adjuvanted Pandemic Vaccine.",
        "lots": [
            {
                "id": "1",
                "description": "Procurement of the Covid-19 Adjuvanted Pandemic Vaccine. Additional information: Contract value is being withheld due to commercial sensitivity (PCR 2015 Reg 50(6)(b) and (c) and FOIA 2000 Section 43). Publication may enable competitors to calculate cost per dose. This will commercially prejudice: (i) the supplier in its negotiations with other national governments; and (ii) the contracting authority in negotiations with other vaccine vendors. It may also impact fair competition between vaccine vendors.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "price"
                        }
                    ]
                },
                "hasOptions": false,
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UK"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Award procedure without prior publication of a call for competition",
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_TECHNICAL",
                "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
            },
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_ADD_DELIVERIES_ORDERED",
                "description": "Additional deliveries by the original supplier ordered under the strict conditions stated in the directive"
            }
        ],
        "procurementMethodRationale": "The award of the contract to Aventis Pharma and GSK is strictly necessary due to absence of competition for technical reasons. Regulation 32 (b)(ii). Furthermore, this Advance Purchase Agreement is the execution of the previous Capacity Reservation Agreement (Please see linked notice)"
    },
    "awards": [
        {
            "id": "026293-2021-2611/09/2020-1",
            "relatedLots": [
                "1"
            ],
            "title": "Advance Purchase Agreement",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-32189",
                    "name": "Aventis Pharma Ltd"
                },
                {
                    "id": "GB-FTS-32190",
                    "name": "GlaxoSmithKline Biologicals S.A"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-5606",
            "name": "Business Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Business Energy and Industrial Strategy"
            },
            "address": {
                "streetAddress": "1 Victoria Street",
                "locality": "London",
                "region": "UKI32",
                "postalCode": "SW1H0ET",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "VTFContracts@beis.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "01",
                        "description": "General public services"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-32189",
            "name": "Aventis Pharma Ltd",
            "identifier": {
                "legalName": "Aventis Pharma Ltd"
            },
            "address": {
                "streetAddress": "Thames Valley Park Drive, Reading",
                "locality": "Berkshire",
                "region": "UK",
                "postalCode": "RG6 1PT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-32190",
            "name": "GlaxoSmithKline Biologicals S.A",
            "identifier": {
                "legalName": "GlaxoSmithKline Biologicals S.A"
            },
            "address": {
                "streetAddress": "Rue de l'Institut 89",
                "locality": "Rixensart",
                "region": "BE",
                "postalCode": "B-1330",
                "countryName": "Belgium"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-14784",
            "name": "Department of Business, Energy and Industrial Strategy",
            "identifier": {
                "legalName": "Department of Business, Energy and Industrial Strategy"
            },
            "address": {
                "streetAddress": "1 Victoria Street, Westminister",
                "locality": "London",
                "postalCode": "SW1H 0ET",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-5606",
        "name": "Business Energy and Industrial Strategy"
    },
    "contracts": [
        {
            "id": "026293-2021-2611/09/2020-1",
            "awardID": "026293-2021-2611/09/2020-1",
            "title": "Advance Purchase Agreement",
            "status": "active",
            "value": {
                "amount": 1,
                "currency": "GBP"
            },
            "dateSigned": "2021-09-20T00:00:00+01:00"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 1
            }
        ]
    },
    "links": [
        {
            "rel": "prev",
            "href": "https://ted.europa.eu/udl?uri=TED:NOTICE:560526-2020:TEXT:EN:HTML"
        }
    ],
    "language": "en"
}